Drug Trial Radar · NCT04842877
Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Feb 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
141
Planned (sponsor's estimate)
Start
Jun 11, 2021
Primary completion
Dec 3, 2024
Study completion Oct 2026
Sponsor
- Lead sponsor
- The Lymphoma Academic Research OrganisationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Daiichi Sankyo
- First posted
- Apr 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, prospective, single arm, non-randomized, open-label, phase 2 clinical study to evaluate safety and efficacy of valemetostat tosylate (DS-3201b) in patients with relapsed or refractory B cell lymphoma with 6 cohorts of patients including 2 biology-driven cohorts. Up to 141 patients will be enrolled in 6 different cohorts (40 patients with aggressive B-cell lymphoma, 41 with follicular lymphoma (FL), 20 with Mantle Cell Lymphoma (MCL) and 20 with other indolent lymphomas, and 20 patients with Hodgkin lymphoma (HL)). FL patients with EZH2 mutant (gain of function mutations) will be enrolled in the cohort 2bis. At least 8 aggressive B-cell lymphoma patients with EZH2 mutant will be enrolled in the cohort 1. The primary endpoint is the overall response rate (ORR) determined by investigator assessment.
Conditions
- Lymphoma, B-Cell
Interventions
Valemetostat tosylateDrug
200mg QD continuously until disease progression, consent withdrawal, unacceptable drug-related toxicity, lost to follow-up, major protocol deviation, pregnancy, termination by sponsor or death, whichever occurs first.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR)Time frame: when mature response rate data have been observed, estimated as no later than 12 months after the last patient in each cohort has received the first dose of study drug
Locations
22 sites in 2 countries. Site status is shown where the registry gives one.
A.Z. Sint Jan AV
Bruges, Belgium
University Hospital Gent
Ghent, Belgium
CH Tourelle Peltzer
Verviers, Belgium
CHU Mont-Godinne
Yvoir, Belgium
CH d'Avignon
Avignon, France
CH de la Côte Basque
Bayonne, France
Institut Bergonié
Bordeaux, France
Institut d'Hématologie de Basse Normandie
Caen, France
Ch Metropole Savoie - Site Chambery
Chambéry, France
CHU d'Estaing
Clermont-Ferrand, France
François Lemonnier
Créteil, France
CHU de Dijon
Dijon, France
Chd de Vendee
La Roche-sur-Yon, France
Clinique Victor Hugo
Le Mans, France
Service des Maladies du Sang - CHRU de Lille
Lille, France
Institut Paoli Calmette
Marseille, France
CHU de Montpellier
Montpellier, France
Gh Region Mulhouse Et Sud Alsace
Mulhouse, France
CHU Hôtel Dieu
Nantes, France
Emmanuel Bachy
Pierre-Bénite, France
CHU Pontchaillou
Rennes, France
Ch de Bretagne Atlantique -
Vannes, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.